Literature DB >> 33489136

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits: Successful treatment for new and rare entity.

Mouna Jerbi1,2, Rym El Fatmi2,3, Hanene Gaied1,2, Dorra Belloumi2,3, Lamia Torjemane2,3, Raja Aoudia4, Rim Goucha1,2, Taieb Ben Abdallah2,4, Tarek Ben Othman3.   

Abstract

Proliferative glomerulonephritis with monoclonal immunoglobulin deposits is a new disorder with undefined treatment modalities. We propose cyclophosphamide-bortezomib-dexamethasone and autologous stem cell transplantation as a therapeutic protocol.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Hematology; Nephrology; Pharmacology

Year:  2020        PMID： 33489136      PMCID： PMC7813026          DOI： 10.1002/ccr3.3439

Source DB:  PubMed          Journal:  Clin Case Rep        ISSN： 2050-0904


  14 in total

1.  Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits.

Authors:  Gauri Bhutani; Samih H Nasr; Samar M Said; Sanjeev Sethi; Fernando C Fervenza; William G Morice; Paul J Kurtin; Francis K Buadi; David Dingli; Angela Dispenzieri; Morie A Gertz; Martha Q Lacy; Prashant Kapoor; Shaji Kumar; Robert A Kyle; S Vincent Rajkumar; Nelson Leung
Journal:  Mayo Clin Proc       Date:  2015-05       Impact factor: 7.616

2.  Long term outcomes in monoclonal gammopathy of renal significance.

Authors:  Akhil Khera; Fotios Panitsas; Faouzi Djebbari; Katja Kimberger; Simon Stern; John Quinn; Neil Rabin; Jaimal Kothari; Bassam Alchi; Richard Haynes; Christopher Winearls; Ian Roberts; Karthik Ramasamy
Journal:  Br J Haematol       Date:  2019-05-29       Impact factor: 6.998

3.  A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Authors:  Ramnika Gumber; Jordana B Cohen; Matthew B Palmer; Sidney M Kobrin; Dan T Vogl; Alan G Wasserstein; Sunita D Nasta; Melissa B Bleicher; Roy D Bloom; Laura Dember; Adam Cohen; Brendan M Weiss; Jonathan J Hogan
Journal:  Kidney Int       Date:  2018-05-11       Impact factor: 10.612

Review 4.  The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient.

Authors:  Jai Radhakrishnan; Daniel C Cattran
Journal:  Kidney Int       Date:  2012-08-15       Impact factor: 10.612

Review 5.  [Classification and therapeutic management of monoclonal gammopathies of renal significance].

Authors:  V Javaugue; I Bouteau; C Sirac; N Quellard; J Diolez; A Colombo; E Desport; L Ecotière; J-M Goujon; J-P Fermand; G Touchard; A Jaccard; F Bridoux
Journal:  Rev Med Interne       Date:  2017-04-27       Impact factor: 0.728

Review 6.  How I treat monoclonal gammopathy of renal significance (MGRS).

Authors:  Jean-Paul Fermand; Frank Bridoux; Robert A Kyle; Efstathios Kastritis; Brendan M Weiss; Mark A Cook; Mark T Drayson; Angela Dispenzieri; Nelson Leung
Journal:  Blood       Date:  2013-10-09       Impact factor: 22.113

7.  Proliferative glomerulonephritis with monoclonal IgG deposits.

Authors:  Samih H Nasr; Anjali Satoskar; Glen S Markowitz; Anthony M Valeri; Gerald B Appel; Michael B Stokes; Tibor Nadasdy; Vivette D D'Agati
Journal:  J Am Soc Nephrol       Date:  2009-05-21       Impact factor: 10.121

Review 8.  Monoclonal gammopathy of renal significance: Diagnostic workup.

Authors:  Sofia O Correia; Sofia Santos; Jorge Malheiro; António Cabrita; La Salete Martins; Josefina Santos
Journal:  World J Nephrol       Date:  2017-03-06

9.  Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.

Authors:  Rio Noto; Nozomu Kamiura; Yuichiro Ono; Sumie Tabata; Shigeo Hara; Hideki Yokoi; Akihiro Yoshimoto; Motoko Yanagita
Journal:  BMC Nephrol       Date:  2017-04-06       Impact factor: 2.388

10.  Bortezomib Maintenance for the Treatment of Monoclonal Gammopathy of Renal Significance.

Authors:  Holly Lee; Peter Duggan; Paola Neri; Jason Tay; Victor H Jimenez-Zepeda
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-01-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.